Navigation Links
Auxilium Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2010 Financial Results, Guidance for 2011
Date:2/10/2011

specialty biopharmaceutical company with a focus on developing and marketing products to predominantly specialist audiences, such as urologists, endocrinologists, certain targeted primary care physicians, hand surgeons, subsets of orthopedic, general, and plastic surgeons who focus on the hand, and rheumatologists.  Auxilium markets XIAFLEX® (collagenase clostridium histolyticum) for the treatment of adult Dupuytren's contracture patients with a palpable cord and Testim® 1%, a testosterone gel, for the topical treatment of hypogonadism.  Auxilium has two projects in clinical development.  XIAFLEX is in phase III of development for the treatment of Peyronie's disease and is in phase II of development for treatment of Frozen Shoulder syndrome (Adhesive Capsulitis).  Auxilium also has rights to pursue additional indications for XIAFLEX.  For additional information, visit http://www.auxilium.com.

SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

In addition to historical facts or statements of current condition, this release contains forward-looking statements within the meaning of the "Safe Harbor" provisions of The Private Securities Litigation Reform Act of 1995, including statements regarding

  • Auxilium's expected financial performance during 2011, including XIAFLEX revenues, Testim revenues, research and development spending, selling, general and administrative expenses, stock-based compensation expenses and net loss;
  • Auxilium's strategic priorities for 2011;
  • the Company's likelihood of becoming a rapidly growing,  profitable and sustainable  biopharmaceutical company;
  • the market size for XIAFLEX and its potential to be a blockbuster opportunity that could provide sustainable long-term growth for the Company;
  • EMA approval of Xiapex in 2011;
  • the extent and duration of patent protection for X
    '/>"/>

  • SOURCE Auxilium Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10

    Related biology technology :

    1. Auxilium Pharmaceuticals to Announce Fourth Quarter and Full Year 2010 Results and Conduct Conference Call on Thursday, February 10, 2011
    2. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
    3. VioQuest Pharmaceuticals, Inc Q2/08 Review Issued by Scimitar Equity, LLC
    4. Rib-X Pharmaceuticals, Inc. Announces Formation of Clinical Advisory Board
    5. Pacira Pharmaceuticals, Inc. Adds Experienced Physician Dr. David St. Peter to Leadership Team
    6. Transcept Pharmaceuticals, Inc. to Present at the Natixis Bleichroeder Second Annual Hidden Gems Conference
    7. Transdel Pharmaceuticals, Inc. Retains The Investor Relations Group
    8. Chemical Engineering Conference Highlights Energy, Biomedicine, Pharmaceuticals, Sustainability and Centennial
    9. Alseres Pharmaceuticals, Inc. Reports Third Quarter 2008 Operational and Financial Results
    10. Johnson & Johnson Completes Acquisition of Omrix Biopharmaceuticals, Inc.
    11. Alseres Pharmaceuticals, Inc. Announces $1 Million Financing
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:3/27/2015)... 2015 The consumption of compound fertilizers ... recession and high prices in 2008. However, the situation ... keeps on gaining momentum now. , To date, the ... than 100,000 thousand tonnes. No considerable growth was registered ... capacity rocketed during 2012-2013, registering 11% growth as against ...
    (Date:3/27/2015)... 27. März 2015  Peter Walter wurde ... Science für seine bahnbrechende Arbeit ausgewählt, die ... transportiert werden, sowie für die Entschlüsselung der ... auf Stress nutzen, der mit der Ansammlung ... Professor für Biochemie an der University of ...
    (Date:3/27/2015)...  Neogen Corporation (NASDAQ: NEOG ) announced today ... plan in accordance with Securities and Exchange Commission rule ... Neogen Corporation, is a minority owner of this entity ... Herbert does not have control of this entity, ... only for a portion of the shares owned by ...
    (Date:3/27/2015)... YORK , March 27, 2015   ... in liquid photopurification, announced today that the Company ... for the continued trading of SurePure ("SURP") securities ... venture marketplace for entrepreneurial and development stage companies. ... Group introduced standards and eligibility requirements designed to ...
    Breaking Biology Technology:World NPK Fertilizers Market Keeps On Gaining Momentum, According to BAC Reports Study Available at MarketPublishers.com 2World NPK Fertilizers Market Keeps On Gaining Momentum, According to BAC Reports Study Available at MarketPublishers.com 3Deutschstämmiger Zellbiologe Peter Walter gewinnt den Vilcek Prize in Biomedical Science 2015 2Deutschstämmiger Zellbiologe Peter Walter gewinnt den Vilcek Prize in Biomedical Science 2015 3Deutschstämmiger Zellbiologe Peter Walter gewinnt den Vilcek Prize in Biomedical Science 2015 4Neogen CEO adopts 10b5-1 Trading Plan 2SurePure Completes Verification and Approved for Trading on the OTCQB Marketplace 2
    ... , SEATTLE, Nov. 19 Omeros Corporation (Nasdaq: OMER ... September 30, 2009. For the three months ended September 30, 2009, ... share, as compared to a net loss of $7.4 million, or ... nine months ended September 30, 2009, the Company reported a net ...
    ... Nov. 19 NeoStem, Inc. (NYSE Amex: NBS ... letter to its shareholders, discussing the Company,s acquisition, on ... an integrated bio-pharmaceutical company based in the People,s Republic ... interest in Suzhou Eyre Pharmaceutical Co. Ltd., CHBP,s primary ...
    ... , , ... GmbH,announced that they have filed on November 16th, 2009 ... orphan drug status designation with the European Medicines Agency,(EMEA). ... advanced Parkinson,s and a serious burden to some of ...
    Cached Biology Technology:Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 2Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 3Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 4Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 5Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 6Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 7Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 8NeoStem Outlines to Shareholders Near-term and Long-term Business Strategies Following Acquisition of Chinese Pharmaceutical Company 2NeoStem Outlines to Shareholders Near-term and Long-term Business Strategies Following Acquisition of Chinese Pharmaceutical Company 3MONITORING FORCE GmbH Requests Acknowledgment of Flibanserin as "Orphan Drug" 2
    (Date:3/26/2015)... The Granite Club, ... club, today announced it has implemented a state-of-the-art access ... for members and staff, while restricting access to authorized ... selected FST,s IMID Access system because it has the ... and staff, in addition to unparalleled security," said ...
    (Date:3/24/2015)... DUBLIN , Mar. 24, 2015 Research and ... addition of the "Global Iris Recognition Market 2015-2019" ... forecast the Global Iris Recognition market to grow at ... This report covers the present scenario and ... for the period 2015-2019. To calculate the market size, ...
    (Date:3/24/2015)... DUBLIN , Mar. 24, 2015 Research and Markets ... "Face and Voice Biometrics - Global Strategic Business Report" report ... for Face and Voice Biometrics in US$ Thousands by the following ... analytics for the US, Canada , ... , Middle East & ...
    Breaking Biology News(10 mins):Granite Club First Private Club in North America to Implement FST Biometrics Secure Access Solution, as Part of Multi-million Dollar Expansion 2Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 2Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 3Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 4Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 5Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 6
    ... Mich.Millions of Americans struggling with psoriasis and psoriatic arthritis ... release of the first National Psoriasis Victor Henschel BioBank ... of Michigan Health System; research that hopes to uncover ... arthritis. A disabling and disfiguring disease of the ...
    ... often as men, but estrogen might not be the reason. ... preliminary findings in the lab of Florida State University researcher ... recently was awarded a five-year, $1.8 million grant from the ... in anxiety. His research team also is working to identify ...
    ... Biologists at the University of California, Riverside have ... a highly heritable trait that can be passed down ... the lab, they found that activity level can be ... plants and animals for particular genetic traits. Their ...
    Cached Biology News:U-M researchers receive largest single collection of psoriasis DNA samples 2Why does anxiety target women more? FSU researcher awarded $1.8 million grant to find out 2Capacity for exercise can be inherited, UC Riverside biologists find 2Capacity for exercise can be inherited, UC Riverside biologists find 3
    Spectrolyse (pL) PAI kit is a two-stage indirect enzymatic assay for the quantitative determination of Plasminogen Activator Inhibitor (PAI-1) activity in plasma. Sample Type: plasma...
    Rabbit anti-CRSP1 (TRAP220), Polyclonal Antibody, Unconjugated Applications: Immunohistochemistry - 1:100 - 1:500...
    ... N-(2-Naphthoyl)-Val-phenylalaninal 2-Naphthoyl-VF-CHO White lyophilized ... GAS. A cell-permeable, reversible inhibitor of γ-secretase. ... (ED 50 = 2.6 μM) ... = 2.7 μM) in HEK293 cells stably ...
    ...
    Biology Products: